Sezary Syndrome (SS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Sezary Syndrome (SS) is a type of
cutaneous T-cell lymphoma, a group of disorders characterized by transforming
T-cells into cancerous cells and their effect on the skin. A small percentage
of SS cases have been associated with human T-lymphotropic viruses type 1 and 2
(HTLV-I/II). Although the exact cause of SS is unknown, chromosomal anomalies,
particularly rearrangements in the 6q23-27 region, leading to changes in the
MYB proto-oncogene and the IL22RA2 gene, have been implicated. SS is more
common in men and usually presents in the fifth decade of life. Patients
typically experience rapid progression of symptoms, which include scaling
erythroderma, leonine facies, severe pruritus, alopecia, ectropium, mild
palmoplantar keratoderma, and nail onychodystrophy. Lymphadenopathy and
hepatosplenomegaly may also be present, along with chills, fatigue, and general
discomfort. Differential diagnoses for SS include mycosis fungoides, psoriasis,
pityriasis rubra pilaris, dermatitis, hypereosinophilic syndrome, adult T-cell
leukemia, and primary skin disorders such as scabies, drug eruption, and
graft-versus-host disease. Prognostic factors for SS include skin
classification, disease stage, elevated LDH levels, advanced age and
comorbidities, male sex, race, peripheral eosinophilia, large cell
transformation, and folliculotropic MF. These factors have been used in
validated prognostic indices such as the CTCL Severity Index (CTCL-SI), the
Cutaneous Lymphoma International Prognostic Index (CLIPi), and the CLIC
Prognostic Index.
·
The incidence of Sezary syndrome in the USA is
about 0.8 to 0.9 cases per million individuals annually.
Thelansis’s “Sezary Syndrome (SS)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2022 To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Sezary Syndrome (SS) treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Sezary Syndrome (SS) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Sezary Syndrome (SS) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of the
decision-making process. It enables business leaders in forward-thinking and
proactive decision-making. Thelansis supports scientific and commercial teams
in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment